Kay-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 27-37

  Duraffour, Sophie ^a   Drillien, Robert ^b   Haraguchi, Kazuhiro ^c   Balzarini, Jan ^a   Topalis, Dimitri ^a   Van Den Oord, Joost J ^d   Andrei, Graciela ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ADENOSINE TRIPHOSPHATE; ANTIVIRUS AGENT; BRINCIDOFOVIR; BROXURIDINE; CIDOFOVIR; KAY 2 41; NUCLEOSIDE DERIVATIVE; TECOVIRIMAT; THYMIDINE KINASE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CONTROLLED STUDY; COWPOX VIRUS; CROSS RESISTANCE; CYTOPATHOGENIC EFFECT; CYTOSTASIS; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE DELETION; GENOTYPE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; ORTHOPOXVIRUS; OSTEOSARCOMA CELL; POXVIRUS INFECTION; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; COWPOX VIRUS; GENOTYPE; MOLECULAR STRUCTURE; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 84891553053     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01601-13     Document Type: Article

References (49)

1. Vogel S, Sardy M, Glos K, Korting HC, Ruzicka T, Wollenberg A. 2012. The Munich outbreak of cutaneous cowpox infection: Transmission by infected pet rats. Acta Derm. Venereol. 92:126-131. http://dx.doi.org/10.2340/00015555-1227.
2. Silva DC, Moreira-Silva EA, Gomes JA, Fonseca FG, Correa-Oliveira R. 2010. Clinical signs, diagnosis, and case reports of Vaccinia virus infections. Braz. J. Infect. Dis. 14:129-134. http://dx.doi.org/10.1590/S1413- 86702010000200003.
3. Bhanuprakash V, Venkatesan G, Balamurugan V, Hosamani M, Yogisharadhya R, Gandhale P, Reddy KV, Damle AS, Kher HN, Chandel BS, Chauhan HC, Singh RK. 2010. Zoonotic infections of buffalopox in India. Zoonoses Public Health 57:e149-e155. http://dx.doi.org/10.1111/j.1863-2378.2009.01314.x.
4. Reynolds MG, Damon IK. 2012. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol. 20:80-87. http://dx.doi.org/10.1016/ j.tim.2011.12.001.
5. Centers for Disease Control and Prevention. 2012. Human orf virus infection from household exposures - United States, 2009-2011.MMWR Morb. Mortal. Wkly. Rep. 61:245-248.
6. Al-Qattan MM. 2011. Orf infection of the hand. J. Hand Surg. Am. 36: 1855-1858. http://dx.doi.org/10.1016/j.jhsa.2011.08.019.
7. de Carvalho CH, de Andrade AL, de Oliveira DH, Lima E, da SilveiraEJ, de Medeiros AM. 2012. Intraoral molluscum contagiosum in a young immunocompetent patient. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 114:e57- e60. http://dx.doi.org/10.1016/j.oooo.2011.10.009.
8. Fiandeiro PT, Attard N. 2013. Koebnerized molluscum contagiosum. QJM 106:1043. http://dx.doi.org/10.1093/qjmed/hcs183.
9. Elsendoorn A, Agius G, Le Moal G, Aajaji F, Favier AL, Wierzbicka- Hainault E, Beraud G, Flusin O, Crance JM, Roblot F. 2011. Severe ear chondritis due to cowpox virus transmitted by a pet rat. J. Infect. 63:391- 393. http://dx.doi.org/10.1016/j.jinf.2011.06.004.
10. Haase O, Moser A, Rose C, Kurth A, Zillikens D, Schmidt E. 2011. Generalizedcowpoxinfection in a patient with Darier disease. Br. J. Dermatol. 164:1116-1118. http://dx.doi.org/10.1111/j.1365-2133.2011.10226.x.
11. Lin HY, Linn G, Liu CB, Chen CJ, Yu KJ. 2010. An immunocompromised woman with severe molluscum contagiosum that responded well to topical imiquimod: A case report and literature review. J. Low Genit. Tract Dis. 14:134-135. http://dx.doi.org/10.1097/LGT.0b013e3181bf1a50.
12. Pelkonen PM, Tarvainen K, Hynninen A, Kallio ER, Henttonen K, Palva A, Vaheri A, Vapalahti O. 2003. Cowpox with severe generalized eruption, Finland. Emerg. Infect. Dis. 9:1458-1461. http://dx.doi.org/10.3201/eid0911.020814.
13. Andrei G, Snoeck R. 2010. Cidofovir activity against poxvirus infections. Viruses 2:2803-2830. http://dx.doi.org/10.3390/v2122803.
14. Hostetler KY. 2010. Synthesis and early development of exadecyloxypropylcidofovir: An oral antipoxvirus nucleoside phosphonate. Viruses 2:2213-2225. http://dx.doi.org/10.3390/v2102213.
15. Centers for Disease Control and Prevention. 2009. Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:532-536.
16. Kaiser J. 2007. Smallpox vaccine. A tame virus runs amok. Science 316: 1418-1419. http://dx.doi.org/10.1126/science.316.5830.1418.
17. Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, O'Mahony R, Almond M, Painter G. 2010. Development of CMX001 for the treatment of poxvirus infections. Viruses 2:2740-2762. http://dx.doi.org/10. 3390/v2122740.
18. Papanicolaou G, Kurtzberg J, Grimley M, Storch GA, Goyal R, Anderson M, Mommeja-Marin H, Painter W. 2011. CMX001 is not nephro-toxic or myelosuppressive in 183 patients with life threatening dsDNA infections including refractory cytomegalovirus, adenovirus, and BK virus, abstr V-499b. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
19. Gammon DB, Snoeck R, Fiten P, Krecmerova M, Holy A, De Clercq E, Opdenakker G, Evans DH, Andrei G. 2008. Mechanism of antiviral drug resistance of vaccinia virus: Identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 82:12520-12534. http://dx.doi.org/10.1128/JVI.01528-08.
20. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holy A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG, van der Zeijst BA, Osterhaus AD. 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439: 745-748. http://dx.doi.org/10.1038/nature04295.
21. Duraffour S, Snoeck R, de Vos R, van Den Oord JJ, Crance JM, Garin D, Hruby DE, Jordan R, De Clercq E, Andrei G. 2007. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 12:1205-1216.
22. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149. http://dx.doi.org/10.1128/JVI.79.20.13139-13149.2005.
23. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE. 2012. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob. Agents Chemother. 56:4900-4905. http://dx.doi.org/10.1128/AAC.00904-12.
24. Srivastav NC, Rai D, Tse C, Agrawal B, Kunimoto DY, Kumar R. 2010. Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2′-deoxynucleoside analogues using in vitro and in vivo models. J. Med. Chem. 53:6180-6187. http://dx.doi.org/10.1021/ jm100568q.
25. Secrist JA, III, Tiwari KN, Riordan JM, Montgomery JA. 1991. Synthesis and biological activity of 2′-deoxy-4′-thio pyrimidine nucleosides. J. Med. Chem. 34:2361-2366. http://dx.doi.org/10.1021/jm00112a007.
26. Dyson MR, Coe PL, Walker RT. 1991. The synthesis and antiviral activity of some 4′-thio-2′-deoxy nucleoside analogues. J. Med. Chem. 34:2782- 2786. http://dx.doi.org/10.1021/jm00113a016.
27. Kern ER, Prichard MN, Quenelle DC, Keith KA, Tiwari KN, Maddry JA, Secrist JA, III. 2009. Activities of certain 5-substituted 4′- thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrob. Agents Chemother. 53:572-579. http://dx.doi.org/10.1128/AAC.01257-08.
28. Rahim SG, Trivedi N, Bogunovic-Batchelor MV, Hardy GW, Mills G, Selway JW, Snowden W, Littler E, Coe PL, Basnak I, Whale RF, Walker RT. 1996. Synthesis and anti-herpes virus activity of 2′-deoxy-4′- thiopyrimidine nucleosides. J. Med. Chem. 39:789-795. http://dx.doi.org /10.1021/jm950029r.
29. Prichard MN, Quenelle DC, Hartline CB, Harden EA, Jefferson G, Frederick SL, Daily SL, Whitley RJ, Tiwari KN, Maddry JA, Secrist JA, III, Kern ER. 2009. Inhibition of herpesvirus replication by 5-substituted 4′-thiopyrimidine nucleosides. Antimicrob. Agents Chemother. 53:5251- 5258. http://dx.doi.org/10. 1128/AAC.00417-09.
30. Prichard MN, Williams AD, Keith KA, Harden EA, Kern ER. 2006. Distinct thymidine kinases encoded by cowpox virus and herpes simplex virus contribute significantly to the differential antiviral activity of nucleoside analogs. Antiviral Res. 71:1-6. http://dx.doi.org/10.1016/j.antiviral.2006.01.013.
31. Solaroli N, Johansson M, Balzarini J, Karlsson A. 2006. Substrate specificity of three viral thymidine kinases (TK): Vaccinia virus TK, feline herpesvirus TK, and canine herpesvirus TK. Nucleosides Nucleotides Nucleic Acids 25:1189-1192. http://dx.doi.org/10.1080/15257770600894451.
32. Caillat C, Topalis D, Agrofoglio LA, Pochet S, Balzarini J, Deville- Bonne D, Meyer P. 2008. Crystal structure of poxvirus thymidylate kinase: An unexpected dimerization has implications for antiviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:16900-16905. http://dx.doi.org/10.1073/pnas.0804525105.
33. Topalis D, Collinet B, Gasse C, Dugue L, Balzarini J, Pochet S, Deville-Bonne D. 2005. Substrate specificity of vaccinia virus thymidylate kinase. FEBS J. 272: 6254-6265. http://dx.doi.org/10.1111/j.1742-4658.2005. 05006.x.
34. Haraguchi K, Takahashi H, Tanaka H, Hayakawa H, Ashida N, Nitanda T, Baba M. 2004. Synthesis and antiviral activities of 1′-carbonsubstituted 4′-thiothymidines. Bioorg. Med. Chem. 12:5309-5316. http://dx.doi.org/10. 1016/j.bmc.2004.07.057.
35. Duraffour S, Andrei G, Topalis D, Krecmerova M, Crance JM, Garin D, Snoeck R. 2012. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus. J. Virol. 86:7310-7325. http://dx.doi.org/10.1128/JVI.00355-12.
36. Carroll DS, Emerson GL, Li Y, Sammons S, Olson V, Frace M, Nakazawa Y, Czerny CP, Tryland M, Kolodziejek J, Nowotny N, Olsen- Rasmussen M, Khristova M, Govil D, Karem K, Damon IK, Meyer H. 2011. Chasing Jenner's vaccine: revisiting cowpox virus classification. PLoS One 6:e23086. http://dx.doi.org/10.1371/ journal.pone.0023086.
37. Pfeffer M, Meyer H, Wernery U, Kaaden OR. 1996. Comparison of camelpox viruses isolated in Dubai. Vet. Microbiol. 49:135-146. http://dx.doi.org/10. 1016/0378-1135(95)00181-6.
38. Ramyar H, Hessami M. 1972. Isolation, cultivation and characterization of camel pox virus. Zentralbl. Veterinarmed. B 19:182-189.
39. Gammon DB, Gowrishankar B, Duraffour S, Andrei G, Upton C, Evans DH. 2010. Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog. 6:e1000984. http://dx.doi.org/10.1371/journal.ppat.1000984.
40. Duraffour S, Snoeck R, Krecmerova M, Van den Oord J, de Vos R, Holy A, Crance JM, Garin D, De Clercq E, Andrei G. 2007. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob. Agents Chemother. 51: 4410-4419. http://dx.doi.org/10.1128/AAC.00838-07.
41. Duraffour S, Matthys P, van den Oord JJ, De Schutter T, Mitera T, Snoeck R, Andrei G. 2011. Study of camelpox virus pathogenesis in athymic nude mice. PLoS One 6:e21561. http://dx.doi.org/10.1371/journal.pone.0021561.
42. Schwarzer H, Kurth A, Hermel M, Plange N. 2013. Severe ulcerative keratitis in ocular cowpox infection. Graefes Arch. Clin. Exp. Ophthalmol. 251:1451-1452. http://dx.doi.org/10.1007/s00417-012-2138-x.
43. Delhon G, Tulman ER, Afonso CL, Lu Z, Concha-Bermejillo A, Lehmkuhl HD, Piccone ME, Kutish GF, Rock DL. 2004. Genomes of the parapoxviruses ORF virus and bovine papular stomatitis virus. J. Virol. 78:168-177. http://dx.doi.org/10. 1128/JVI.78.1.168-177.2004.
44. El Omari K, Solaroli N, Karlsson A, Balzarini J, Stammers DK. 2006. Structure of vaccinia virus thymidine kinase in complex with dTTP: Insights for drug design. BMC Struct. Biol. 6:22. http://dx.doi.org/10.1186 /1472-6807-6-22.
45. Segura-Pena D, Lutz S, Monnerjahn C, Konrad M, Lavie A. 2007. Binding of ATP to TK1-like enzymes is associated with a conformational change in the quaternary structure. J. Mol. Biol. 369:129-141. http://dx.doi.org/10.1016/j. jmb.2007.02.104.
46. Segura-Pena D, Lichter J, Trani M, Konrad M, Lavie A, Lutz S. 2007. Quaternary structure change as a mechanism for the regulation of thymidine kinase 1-like enzymes. Structure 15:1555-1566. http://dx.doi.org/10.1016/j.str. 2007.09.025.
47. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL. 2000. Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7:66-73. http://dx.doi.org/10.1038/sj.cgt.7700075.
48. Smee DF, Gowen BB, Wandersee MK, Wong MH, Skirpstunas RT, Baldwin TJ, Hoopes JD, Sidwell RW. 2008. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int. J. Antimicrob. Agents 31:352-359. http://dx.doi.org/10.1016/j.ijantimicag.2007.11.013.
49. Fan X, Zhang X, Zhou L, Keith KA, Prichard MN, Kern ER, Torrence PF. 2006. Toward orthopoxvirus countermeasures: A novel heteromorphic nucleoside of unusual structure. J. Med. Chem. 49:4052-4054. http://dx.doi.org/10.1021/ jm060404n